AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$ANTX

AN2 Therapeutics, Inc.

Price · $ANTXvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $ANTX in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $ANTX in the last 30 days.

Top stories · $ANTXMore →
APR 9·TipRanksLow

AN2 Therapeutics Launches New $80 Million ATM Program

AN2 Therapeutics (ANTX) has established a new $80 million at-the-market (ATM) stock sale program with Jefferies to issue common stock. This move replaces a previous ATM agreement with TD Securities, under which the company had raised approximately $20 million. The company's stock currently holds a Hold rating with a $3.50 price target from analysts, while TipRanks' AI Analyst Spark rates ANTX as Neutral due to weak financial performance despite positive technicals.

MAR 9·BioSpace

AN2 Therapeutics Announces $40 Million Private Placement Financing

AN2 Therapeutics, a clinical-stage biopharmaceutical company, announced a private placement financing expected to generate approximately $40 million in gross proceeds. The financing includes the sale of common stock and pre-funded warrants to new and existing institutional investors, including Coastlands Capital, Commodore Capital, and Vivo Capital. The proceeds will support the company's development of novel small molecule therapeutics utilizing its boron chemistry platform.

JAN 30·TipRanks

AN2 Therapeutics adjusts leadership roles and executive compensation

AN2 Therapeutics (ANTX) has appointed Sarah Williams as Principal Accounting Officer with an increased salary, effective February 1, 2026. Simultaneously, CFO Lucy Day's salary will be reduced as part of the company's cost-saving efforts, while her other employment terms remain largely unchanged. The company's stock currently holds a "Hold" rating with a $1.00 price target based on analyst forecasts.

News on $ANTX

All news →